Borosil Scientific Investor Presentation: Key Takeaways
Q2FY27 consolidated sales ₹115.0 Cr (+7.6%), EBITDA ₹11.0 Cr (+29.4%), PAT ₹5.3 Cr (+86.3%). Standalone PAT fell 16.9% on input costs.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Q2FY27 consolidated sales ₹115.0 Cr (+7.6%), EBITDA ₹11.0 Cr (+29.4%), PAT ₹5.3 Cr (+86.3%). Standalone PAT fell 16.9% on input costs.
Borosil Scientific reported Q1FY27 consolidated net sales of Rs. 106.8 Cr (11.2% YoY growth). Strategy focuses on diversifying from lab glassware into high-margin process equipment and pharma packaging.
Borosil Scientific delivered strong Q4FY26 results with Consolidated Net Sales up 10.6% and EBITDA up 87.6% YoY, driven by operational efficiency and scientific segment growth.